EUVIMEDEUVIMED entdecken
Crossref

Long-Term Observation of Monotherapy (Methotrexate) in Rheumatoid Arthritis

Sheikh Javeed Ahmad, Ruquiya Ali, Abdul Hamid Rather, Mohammad Kaleem Ul Haque, Tufail Muzaffar

International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)

DOI: 10.25258/ijcpr.18.5.208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Sheikh Javeed Ahmad und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis is most common autoimmune inflammatory joint disease of unknown etiology. Long-term methotrexate use in rheumatoid arthritis (RA) is highly effective at slowing joint damage and inducing remission. A long-term prospective observational, controlled, and non-comparative study was conducted on 310 patients with rheumatoid arthritis fulfilling the American College of Rheumatology (ACR) criteria to observe the longterm efficacy and toxicity of low-dose methotrexate (MTX) over a period of 36 months to 48 months. Steroids, and NSAIDs were tapered gradually in all patients over a period of 8 weeks. Clinical improvement occurred at 6– 8 weeks in 210 patients (68%), while remission was achieved in the remaining 100 patients (32%) over the period of 12 weeks. Mild toxicity was observed in 2.5% of patients and was amenable to folic acid therapy. A small number of patients developed transient bone marrow depression and transient elevation of liver enzymes, neither of which necessitated withdrawal of the drug. Conclusion: The study concludes that methotrexate remains the primary and most effective disease-modifying anti-rheumatic drug (DMARD) for the management of rheumatoid arthritis.

Zitieren

APA

Ahmad, S. J., Ali, R., Rather, A. H., Haque, M. K. U., & Muzaffar, T. (2026). Long-Term Observation of Monotherapy (Methotrexate) in Rheumatoid Arthritis. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.208

Vancouver

Ahmad SJ, Ali R, Rather AH, Haque MKU, Muzaffar T. Long-Term Observation of Monotherapy (Methotrexate) in Rheumatoid Arthritis. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.208

BibTeX
@article{Ahmad2026,
  author = {Ahmad, Sheikh Javeed and Ali, Ruquiya and Rather, Abdul Hamid and Haque, Mohammad Kaleem Ul and Muzaffar, Tufail},
  title = {Long-Term Observation of Monotherapy (Methotrexate) in Rheumatoid Arthritis},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {05},
  doi = {10.25258/ijcpr.18.5.208}
}
Kostenlos starten →